Cargando…

Demonstrating the value of cancer biomarkers at the population level

Detalles Bibliográficos
Autor principal:	Gandjour, Afschin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9135825/ https://www.ncbi.nlm.nih.gov/pubmed/35551552 http://dx.doi.org/10.1007/s10198-022-01474-6

Ejemplares similares

Willingness to pay for new medicines: a step towards narrowing the gap between NICE and IQWiG
por: Gandjour, Afschin
Publicado: (2020)

Impact of the introduction of the AMNOG law on launch delays of new drugs in Germany: a comment
por: Gandjour, Afschin
Publicado: (2023)

Value-based pricing of a COVID-19 vaccine
por: Gandjour, Afschin
Publicado: (2022)

The clinical and economic value of a successful shutdown during the SARS-CoV-2 pandemic in Germany
por: Gandjour, Afschin
Publicado: (2022)

The price of curing cancer
por: Gandjour, Afschin
Publicado: (2021)

Benefits, risks, and cost-effectiveness of COVID-19 self-tests from a consumer’s perspective
por: Gandjour, Afschin
Publicado: (2022)

Comment on “Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective”
por: Gandjour, Afschin
Publicado: (2022)

Was EU’s COVID-19 vaccine procurement strategy irrational? A re-analysis based on cost-effectiveness considerations
por: Gandjour, Afschin
Publicado: (2022)

COVID-19 and the forgone health benefits of elective operations
por: Gandjour, Afschin
Publicado: (2022)

Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results
por: Gandjour, Afschin
Publicado: (2020)

A proportional rule for setting reimbursement prices of new drugs and its mathematical consistency
por: Gandjour, Afschin
Publicado: (2020)

How Many Intensive Care Beds are Justifiable for Hospital Pandemic Preparedness? A Cost-effectiveness Analysis for COVID-19 in Germany
por: Gandjour, Afschin
Publicado: (2021)

Deterministic Sensitivity Analysis Under Ignorance
por: Gandjour, Afschin
Publicado: (2021)

Financial Incentives in the Path to Recovery from the COVID-19 Pandemic
por: Gandjour, Afschin
Publicado: (2021)

A parsimonious model to validate cost-effectiveness analyses on preventive health care
por: Gandjour, Afschin
Publicado: (2021)

A Model-Based Estimate of the Cost-Effectiveness Threshold in Germany
por: Gandjour, Afschin
Publicado: (2023)

Optimal allocation of scarce PCR tests during the COVID-19 pandemic
por: Gandjour, Afschin
Publicado: (2023)

Long COVID: Costs for the German economy and health care and pension system
por: Gandjour, Afschin
Publicado: (2023)

Pharmaceutical expenditure and gross domestic product: Evidence of simultaneous effects using a two‐step instrumental variables strategy
por: Shaikh, Mujaheed, et al.
Publicado: (2018)

Predictors of negotiated prices for new drugs in Germany
por: Gandjour, Afschin, et al.
Publicado: (2020)

Cost-Effectiveness of Angiotensin-Converting Enzyme Inhibitors for the Prevention of Diabetic Nephropathy in The Netherlands – A Markov Model
por: Adarkwah, Charles Christian, et al.
Publicado: (2011)

Costs of patients with chronic kidney disease in Germany
por: Gandjour, Afschin, et al.
Publicado: (2020)

Value Insider Season 1 Episode 6: How Will Market Access and Value Demonstration Evolve? (Future Outlook) [Podcast]
por: Kanavos, Panos G, et al.
Publicado: (2022)

The value of demonstration projects for new interventions: The case of human papillomavirus vaccine introduction in low- and middle-income countries
por: Howard, N., et al.
Publicado: (2016)

Quantifying the added value of new biomarkers: how and how not
por: Cook, Nancy R.
Publicado: (2018)

Prognostic value of biomarkers in primary small cell carcinoma of the esophagus
por: Wang, Yan, et al.
Publicado: (2020)

Expansion of a national Covid-19 alert level system to improve population health and uphold the values of Indigenous peoples
por: Kvalsvig, Amanda, et al.
Publicado: (2021)

Regional cancer centre demonstrates voluntary conformity with the national Radiation Oncology Practice Standards
por: Manley, Stephen, et al.
Publicado: (2015)

Integrative Medicine Demonstrates Advantage in COVID-19 Treatment
por: Cheng, Yung-Chi
Publicado: (2020)

Demonstrating the sustainability of capacity strengthening amidst COVID-19
por: Abomo, P, et al.
Publicado: (2021)

Looking beyond the Lamppost: Population-Level Primary Prevention of Breast Cancer
por: McLoughlin, Gabriella M., et al.
Publicado: (2020)

Current Evidence Demonstrates That Monkeypox Is a Sexually Transmitted Infection
por: Allan-Blitz, Lao-Tzu, et al.
Publicado: (2023)

Image registration: Required for all ophthalmic imaging as demonstrated by optoretinography
por: Schachar, Ronald A., et al.
Publicado: (2023)

The value of screening in patient populations with high prevalence of a disorder
por: Goldberg, David
Publicado: (2014)

Conditional mouse models demonstrate oncogene-dependent differences in tumor maintenance and recurrence
por: Tilli, Maddalena T, et al.
Publicado: (2003)

The Brighton declaration: the value of non-communicable disease modelling in population health sciences
por: Webber, Laura, et al.
Publicado: (2014)

Commentary on “Cervical Inclination Angle: Normative Values in an Adult Multiethnic Asymptomatic Population”
por: Noh, Sung Hyun, et al.
Publicado: (2023)

Cancer biomarkers and targeted therapies
por: Shen, Zhiyuan
Publicado: (2013)

Pink beam crystallography demonstrated in SFX
por: Nakane, Takanori
Publicado: (2021)

Cell therapy demonstrates promise for acute respiratory distress syndrome - but which cell is best?
por: Curley, Gerard F, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_d6ml1adm30c7mvrhjkcs18g6hc